Management of chronic hepatitis C virus infection: A new era of disease control

Internal Medicine Journal

Volumn 34, Issue 6, 2004, Pages 324-337

  Teoh, N C ^a   Farrell, G C ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Cirrhosis; Clinical outcome; Hepatitis C virus; Hepatocellular carcinoma; Pegylated interferon; Ribavirin; Treatment side effects; Type 2 diabetes mellitus; Virological monitoring

Indexed keywords

ALCOHOL; BETA INTERFERON; LONG ACTING DRUG; PEGINTERFERON; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

ALCOHOL CONSUMPTION; CANCER RISK; CLINICAL FEATURE; COMORBIDITY; COUGHING; DEPRESSION; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG RESPONSE; DYSPNEA; ERYTHEMA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; GOUT; HEMOLYTIC ANEMIA; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; INSULIN RESISTANCE; LIFESTYLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MENTAL DISEASE; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOMES RESEARCH; PHYSICIAN; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RELAPSE; REVIEW; RISK FACTOR; RISK REDUCTION; SOCIAL PSYCHOLOGY; TERATOGENICITY; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT CONTRAINDICATION; VIREMIA;

HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; RIBAVIRIN;

EID: 3242789384     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2004.00615.x     Document Type: Review

References (108)

1. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002. Hepatology 2002; 36 Suppl 1: S3-20.
2. Farrell GC. Hepatitis C, other liver disorders, and liver health. A practical guide. Sydney: Maclennan and Petty; 2002.
3. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36 Suppl 1:521-9.
4. Law MG, Batey RG. Injecting drug use in Australia: needle/ syringe programs prove their worth, but hepatitis C still on the increase. Med J Aust 2003; 173: 197-8.
5. Cordoba J, Flavia M, Jacas C, Sauleda S, Esteban JI, Vargas V et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003; 39: 231-8.
6. Ware JE, Bayliss MS, Mannoucchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology 1999; 30: 550-55.
7. Rodger AJ, Jolley D, Thompson SC, Lanigan SC, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 29: 1299-301.
8. Loveday S, Deakin G, Neophyton D. Meaning for the person. In: Hepatitis C. A Management Guide for General Practitioners. Aust Fam Physician 1999; 28 (Special Issue): SI51-6.
9. El-Sarag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology2002; 123: 476-82.
10. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-8.
11. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland D, Marcellin P et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study. Hepatology 2002; 36: 973-7.
12. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36 Suppl 1: S179-84.
13. Treloar CJ, Hopwood MN, Loveday SK. Hepatitis C-related discrimination in healthcare. Report of the Third Australasian Conference on Hepatitis C, Melbourne, March 2002. Med J Aust 2002; 177: 233-4.
14. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-6.
15. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31: 17-24.
16. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483-91.
17. Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J et al. The effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol 2004; 99: 636-44.
18. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003; 38: 493-502.
19. Omata M, Shiratori Y. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. J Gastroenterol Hepatol 2000; 15 Suppl: E134-40.
20. Khan MH, Farrell GC, Byth K, Lin R, Weltman MD, George J et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 513-20.
21. Hirsch KR, Wright TL. 'Silent killer' or benign disease? The dilemma of hepatitis C virus outcomes. Hepatology 2000; 31: 536-7.
22. Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust 2000; 173: 403-5.
23. Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol 2003; 32: 717-24.
24. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38: 50-56.
25. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-33.
26. Gumber SC, Chopra S. Hepatitis C: A multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123: 615-20.
27. Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999; 31: 39-42.
28. El-Sarag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36: 1439-45.
29. Rasul I, Shepherd FA, Kamel-Reid S, Karjden M, Pantalony D, Heathcote EJ. Detection of occult low-grade B-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology 1999; 29: 543-7.
30. Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 2002; 36: 978-85.
31. Hermine O, Lefrere F, Bronowicki J-P, Mariette X, Joneau K, Eclache-Saundreau V et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
32. Streiff MB, Mehta S, Thomas DL. Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology 2002; 35: 947-52.
33. Adinolfi LE, Giordano MG, Adreana A, Tripodi MF, Marracino M, Gambardella M et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113: 590-95.
34. Roy KM, Bagg J. Hepatitis C and oral disease: a critical review. Oral Dis 1999; 5: 270-77.
35. Oldach D. Multidose jeopardy: HCV transmission risk and management of acute HCV in hospital settings. Hepatology 2002; 36: 1020-21.
36. Forns X, Bukh J, Purcell RH. The challenge of developing a vaccine against hepatitis C virus. J Hepatol 2002; 37: 648-95.
37. Freeman A, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR et al. Estimating progression to cirrhosis in patients with chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16.
38. Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288-92.
39. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37: 837-42.
40. Rai R, Wilson LE, Astemborski J, Anania F, Torbenson M, Spoler C et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002; 35: 1247-55.
41. Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous virus clearance and chronic HCV infection. Gut 2001; 49: 423-30.
42. Ostopowicz G, Watson KJR, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27: 1730-35.
43. Poynard T, Ratzui V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-39.
44. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47-56.
45. Adinolfi LE, Gambardella M, Andreana A, Tripode MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
46. Hui J, Sud A, Farrell GC, Bandara P, Byth K, Kench JG et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695-704.
47. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97: 2408-14.
48. Hourigan L, Macdonald G, Purdie D, Whitehall VH, Shorthouse C, Clouston A et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-19.
49. Danta M, Dore GJ, Hennessy L, Li Y, Vickers CR, Harley H et al. Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection. Med J Aust 2002; 177: 240-45.
50. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248-52.
51. Lagging LM, Westin J, Svensson E, Aires N, Dhillon AP, Lindh M et al. Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 2002; 22: 136-44.
52. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-36.
53. Coverdale S, Samarasinghe D, Lin R, Kench J, Byth K, Khan MH et al. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C; value for predicting fibrotic progression. Am J Gastroenterol 2003; 98: 1384-90.
54. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997; 4: 199-208.
55. Giannini E, Borro P, Botta F, Fumagalli A, Malfatti F, Podesta E et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol 2002; 37: 572-7.
56. Hui J, Kench J, Farrell GC, Lin R, Samarasinghe D, Lin R et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002; 17: 873-81.
57. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-72.
58. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
59. Negro F. Hepatitis C virus and liver steatosis: Is it the virus? Yes it is, but not always. Hepatology 2002; 36: 1050-52.
60. Hwang SJ, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 2001; 16: 190-95.
61. Kaba S, Dutta U, Byth K, Crewe EB, Khan MH, Coverdale SA et al. Molecular epidemiology of hepatitis C in Australia. J Gastroenterol Hepatol 1998; 13: 914-20.
62. Thomas DL. Hepatitis and immunodeficiency virus infection. Hepatology 2002; 36: S201-9.
63. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138: 197-207.
64. Weltman MD, Brotodihardjo A, Crewe EB, Farrell GC, Bilous M, Grierson JM et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995; 2: 39-45.
65. Lin R, Dutta U, Kaba S, Kench J, Crewe E, Coverdale S et al. Effects of hepatitis G virus coinfection on severity of hepatitis C. Relationship to risk factors and response to interferon treatment J Gastroenterol Hepatol 1998; 13: 773-80.
66. Okuda K. Is GVB-C (hepatitis G virus) an innocent bystander? J Gastroenterol Hepatol 1998; 13: 763-6.
67. Hickman IJ, Clouston AD, MacDonald GA, Purdie DM, Prins JB, Ash S et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51: 89-94.
68. Demetrius AJ, Ruppert K. Pathologist's perspective on the liver needle biopsy size? J Hepatol 2003; 39: 275-7.
69. Scheuer PJ. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 2003; 38: 1449-57.
70. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
71. Afdhal NH. Diagnosing fibrosis in hepatitis C. Is the pendulum swinging from biopsy to blood tests? Hepatology 2003; 37: 972-4.
72. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto LK, Martinez-Bauer E et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
73. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
74. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92: 1302-4.
75. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C. et al. Fibrosis prediction in chronic hepatitis C. Utility of a fibrosis index incorporating measures of insulin resistance. Hepatology 2004 (in press).
76. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
77. DiBisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36 Suppl 1: S121-7.
78. Farrell GC. Consensus among consensus conferences on management of hepatitis C: what we knew then and are still sure about, what we are newly sure about, and what we still need to know. J Gastroenterol Hepatol 2000; 15 Suppl: E126-9.
79. Heathcote EJ, Shiftman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.
80. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. A randomised trial. Lancet 2001; 358: 958-65.
81. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-37.
82. Siebert U, Srocznski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-32.
83. Dutta U, Byth K, Kench J, Khan MH, Coverdale SA, Weltman M et al. Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C. A case-control study. Aust N Z J Med 1999; 29: 300-7.
84. Farrell GC. Hepatocellular carcinoma after sustained response to interferon in non-cirrhotic hepatitis C. Flaws in the cure, or a clue to the flaws? J Gastroenterol Hepatol 1999; 14: 833-7.
85. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C. A systematic review. Hepatology 2002; 36 Suppl 1: S84-92.
86. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C et al. Adherence to combination therapy enhances sustained response in genotype 1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
87. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
88. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897-903.
89. Hong Z. The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact? Hepatology 2003; 38: 807-10.
90. McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002; 35: 688-93.
91. Kumar D, Wallington-Beddoe C, George J, Lin R, Samarasinghe D, Liddle C et al. Effectiveness of interferon alpha-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting. Med J Aust 2003; 178: 267-71.
92. Kontorinis N, Garas G, Young J, Speers D, Chester BP, MacQuillan GC et al. Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic. Intern Med J 2003; 33: 500-4.
93. Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Sette H et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. J Hepatol 2002; 36 Suppl 1:3.
94. Fontana RJ, Lok ASF. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36: S57-64.
95. Chutaputti A. Adverse effects and other safety aspects of the hepatitis C antivirals. J Gastroenterol Hepatol 2000; 15: E156-63.
96. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 Suppl 1: S237-44.
97. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.
98. Sugimoto K, Stadanlick J, Ikeda F, Bresinger C, Furth EE, Alter HJ et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003; 37: 590-99.
99. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: The impact of novel genotypes and race on treatment outcome. Hepatology 2002; 36: 1259-65.
100. Wong V, Fu AXL, George J, Cheung NW. Two forms of thyrotoxicosis induced by interferon alpha therapy in the treatment of chronic viral hepatitis. Clin Endocrinol 2002; 56: 793-8.
101. Teubler G, Pascu M, Berg T, Lafrenz M, Pausch J, Kullmann F et al. Randomized, controlled trial with IFN-a combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol 2003; 39: 606-13.
102. Batey RG, Bensoussan A, Fan YY, Bollipo S, Hossain MA. Preliminary report of a randomised, double-placebo controlled trial of a Chinese herbal medicine preparation CH100 in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 1998; 13: 244-7.
103. Lo GH, Lai KH, Cheng JS, Lin CK, Hsu PI, Chiang HT. Prophylactic banding ligation of high-risk esophageal varices in patients with cirrhosis: a prospective, randomized trial. J Hepatol 1999; 31: 451-6.
104. Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999; 340: 988-93.
105. Macdonald GA, Peduto AJ. Magnetic resonance imaging (MRI) and diseases of liver and biliary tract. Part 1. Basic principles, MRI in the assessment of diffuse and focal hepatic disease. J Gastroenterol Hepatol 2000; 15: 980-91.
106. Shiftman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002; 36: S128-34.
107. Strader DB. Understudied populations with hepatitis C. Hepatology 2002; 36: S226-36.
108. Chen RY, Desmond PV, Locarnini SA. Emerging therapies of hepatitis B and C. J Gastroenterol Hepatol 2002; 17: S471-81.